AR089507A1 - VARIANTES DE Fc DE INMUNOGLOBULINAS - Google Patents
VARIANTES DE Fc DE INMUNOGLOBULINASInfo
- Publication number
- AR089507A1 AR089507A1 ARP120105031A ARP120105031A AR089507A1 AR 089507 A1 AR089507 A1 AR 089507A1 AR P120105031 A ARP120105031 A AR P120105031A AR P120105031 A ARP120105031 A AR P120105031A AR 089507 A1 AR089507 A1 AR 089507A1
- Authority
- AR
- Argentina
- Prior art keywords
- variants
- immunoglobulin
- fcrn
- binding affinity
- immunoglobulins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110147683A KR102041412B1 (ko) | 2011-12-30 | 2011-12-30 | 면역글로불린 Ｆｃ 단편 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089507A1 true AR089507A1 (es) | 2014-08-27 |
Family
ID=48698034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120105031A AR089507A1 (es) | 2011-12-30 | 2012-12-27 | VARIANTES DE Fc DE INMUNOGLOBULINAS |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140357843A1 (https=) |
| EP (2) | EP2802604A4 (https=) |
| JP (2) | JP6448368B2 (https=) |
| KR (1) | KR102041412B1 (https=) |
| CN (2) | CN104039831B (https=) |
| AR (1) | AR089507A1 (https=) |
| TW (2) | TWI680137B (https=) |
| WO (1) | WO2013100702A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| DK2825633T3 (da) * | 2012-03-12 | 2019-05-20 | Hanmi Science Co Ltd | Fremgangsmåde til dyrkning af E. coli-celler til høj densitet |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| KR101895634B1 (ko) * | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
| AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| SG11201605203UA (en) | 2013-12-24 | 2016-07-28 | Argen X N V | Fcrn antagonists and methods of use |
| MX2016010951A (es) | 2014-03-05 | 2016-11-29 | Ucb Biopharma Sprl | Proteinas de fc multimericas. |
| MX387560B (es) * | 2014-03-31 | 2025-03-18 | Hanmi Pharmaceutical Co Ltd | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. |
| CA2945882A1 (en) * | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN106222129A (zh) * | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技（上海）有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| WO2018107117A1 (en) | 2016-12-09 | 2018-06-14 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| CN110506056A (zh) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体和其使用方法 |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| PE20210119A1 (es) | 2017-10-31 | 2021-01-19 | Staten Biotechnology B V | Anticuerpos anti-apoc3 y metodos de uso de estos |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| WO2019235426A1 (ja) * | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| KR20210029210A (ko) | 2018-06-29 | 2021-03-15 | 악스톤 바이오사이언시스 코퍼레이션 | 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| MA50586A (fr) | 2018-08-09 | 2020-09-16 | Regeneron Pharma | Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| EP4069724A4 (en) * | 2019-12-04 | 2023-11-29 | Spectrum Pharmaceuticals, Inc. | METHOD OF TREATMENT USING G-CSF PROTEIN COMPLEX |
| KR20250142943A (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| LT3972987T (lt) | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| BR112022023609A2 (pt) * | 2020-05-22 | 2023-02-07 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| EP4197560A4 (en) * | 2020-08-14 | 2025-11-26 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising a persistent triple activator conjugate used as the active ingredient. |
| EP4373861A4 (en) | 2021-07-23 | 2025-08-20 | Akston Biosciences Corp | INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| CN117886927A (zh) * | 2022-10-14 | 2024-04-16 | 华南理工大学 | 一种提高血液半衰期的免疫球蛋白Fc变体及其应用 |
| CN121532432A (zh) * | 2023-05-10 | 2026-02-13 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 免疫治疗蛋白 |
| WO2024229535A1 (en) * | 2023-05-10 | 2024-11-14 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Immunotherapeutic proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) * | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| WO2005037867A1 (en) * | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| ES2383300T3 (es) * | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| AU2005274905B2 (en) * | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101098890B (zh) * | 2004-11-12 | 2012-07-18 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006130834A2 (en) * | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| KR100824505B1 (ko) | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| JP5913980B2 (ja) * | 2008-10-14 | 2016-05-11 | ジェネンテック， インコーポレイテッド | 免疫グロブリン変異体及びその用途 |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
-
2011
- 2011-12-30 KR KR1020110147683A patent/KR102041412B1/ko active Active
-
2012
- 2012-12-27 AR ARP120105031A patent/AR089507A1/es unknown
- 2012-12-28 CN CN201280066663.2A patent/CN104039831B/zh active Active
- 2012-12-28 JP JP2014550023A patent/JP6448368B2/ja active Active
- 2012-12-28 CN CN201810057954.4A patent/CN108465111A/zh active Pending
- 2012-12-28 EP EP12861250.4A patent/EP2802604A4/en not_active Ceased
- 2012-12-28 WO PCT/KR2012/011739 patent/WO2013100702A1/en not_active Ceased
- 2012-12-28 TW TW101150928A patent/TWI680137B/zh active
- 2012-12-28 TW TW108141386A patent/TW202012449A/zh unknown
- 2012-12-28 EP EP20150344.8A patent/EP3656792B1/en active Active
- 2012-12-28 US US14/369,616 patent/US20140357843A1/en not_active Abandoned
-
2018
- 2018-08-03 JP JP2018146978A patent/JP6689329B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2802604A4 (en) | 2016-02-17 |
| TW202012449A (zh) | 2020-04-01 |
| JP6448368B2 (ja) | 2019-01-09 |
| KR102041412B1 (ko) | 2019-11-11 |
| EP3656792C0 (en) | 2024-07-03 |
| CN104039831A (zh) | 2014-09-10 |
| WO2013100702A1 (en) | 2013-07-04 |
| EP2802604A1 (en) | 2014-11-19 |
| JP6689329B2 (ja) | 2020-04-28 |
| CN104039831B (zh) | 2018-02-23 |
| EP3656792B1 (en) | 2024-07-03 |
| CN108465111A (zh) | 2018-08-31 |
| KR20130078633A (ko) | 2013-07-10 |
| US20140357843A1 (en) | 2014-12-04 |
| EP3656792A1 (en) | 2020-05-27 |
| TW201336865A (zh) | 2013-09-16 |
| TWI680137B (zh) | 2019-12-21 |
| JP2019001793A (ja) | 2019-01-10 |
| JP2015507628A (ja) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089507A1 (es) | VARIANTES DE Fc DE INMUNOGLOBULINAS | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| AR129651A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| CY1120637T1 (el) | Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40 | |
| CY1120137T1 (el) | Ενεσιμα σκευασματα βοτουλινικης τοξινης | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
| EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
| CY1121335T1 (el) | Anti-cxcr3 αντισωματα | |
| EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| PE20141019A1 (es) | Nuevos inmunoconjugados | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| EA201491569A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| AR101829A1 (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 | |
| CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| MX384191B (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
| EA202193044A2 (ru) | Способы лечения таупатии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |